Healthy supply of epinephrine injections available to hospitals and clinics

Sandoz Inc., a Novartis Division, announced that its large wholesaler customers are now fully stocked to supply hospitals and clinics with SYMJEPI (epinephrine) 0.3 mg Injection inventory in the U.S. for the emergency treatment of allergic reactions (Type 1), including anaphylaxis.

SYMJEPI is currently available to patients through hospitals and clinics only but the company said it is actively preparing for the U.S. introduction of SYMJEPI 0.3 mg and 0.15 mg Injection into the retail market to enable patients to purchase at local pharmacies.

Sandoz said it also launched the SYMJEPI Savings Program, in which eligible patients can get the life-saving medicine for free. The program will continue to be distributed directly through hospital pharmacies until SYMJEPI is available in the retail market.